<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05042375</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-331</org_study_id>
    <nct_id>NCT05042375</nct_id>
  </id_info>
  <brief_title>A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Open-Label, Controlled, Multi-center Phase Ⅲ Study of Camrelizumab Combined With Famitinib Malate Versus Pembrolizumab in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, and safety of camrelizumab combined&#xD;
      with famitinib malate vs. pembrolizumab in treatment naïve subjects with programmed&#xD;
      death-ligand 1(PD-L1)-positive recurrent or metastatic non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Camrelizumab Combined with Famitinib Malate versus Pembrolizumab</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS assessed by BIRC</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression as determined by IRC with use of RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>up to 4 years</time_frame>
    <description>OS is the time interval from the date of randomization to death due to any reason or lost of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS assessed by investigator</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Disease Control Rate, determined using RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Duration of Response, determined using RECIST v1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTF</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Time to Treatment Failure, defined as the time from randomization to treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>from the first drug administration to within 90 days for the last SHR-1210 dose</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">706</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>camrelizumab + famitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab + famitinib</intervention_name>
    <description>Camrelizumab for injection, 200 mg; Famitinib malate capsules, 20 mg.</description>
    <arm_group_label>camrelizumab + famitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>pembrolizumab 200 mg.</description>
    <arm_group_label>pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab</intervention_name>
    <description>Camrelizumab for injection, 200 mg.</description>
    <arm_group_label>camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a histologically or cytologically confirmed diagnosis of metastatic NSCLC (stage&#xD;
             IV according to the TNM staging criteria [8th edition] published by the International&#xD;
             Association for the Study of Lung Cancer [IASLC]), or NSCLC that recurs after curable&#xD;
             surgery, radiotherapy, or radiochemotherapy.&#xD;
&#xD;
          2. Have measurable disease based on RECIST v1.1.&#xD;
&#xD;
          3. ECOG PS score: 0-1.&#xD;
&#xD;
          4. Have a life expectancy of at least 3 months.&#xD;
&#xD;
          5. Non-surgically sterilized female subjects or women of childbearing potential must be&#xD;
             negative for a serum pregnancy test within 3 days prior to the first dose and must be&#xD;
             non-lactating. Female subjects of childbearing potential and male subjects with&#xD;
             partners of childbearing potential must agree to take highly effective contraceptive&#xD;
             measures during the study period and within 6 months after the last dose of study&#xD;
             drugs.&#xD;
&#xD;
          6. Have voluntarily agreed to participate by giving written informed consent for the&#xD;
             study, have good compliance, and cooperate with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Accompanied with EGFR activating mutation, ALK fusion gene positive or ROS1 mutation.&#xD;
&#xD;
          2. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or&#xD;
             ascites.&#xD;
&#xD;
          3. Have known history of prior malignancy in the past 3 years.&#xD;
&#xD;
          4. Have had an allogeneic tissue/solid organ transplant.&#xD;
&#xD;
          5. Have active pulmonary tuberculosis.&#xD;
&#xD;
          6. Have clinical symptoms of the heart or heart diseases that are not well controlled.&#xD;
&#xD;
          7. Have hypertension which cannot be well controlled by antihypertensives&#xD;
&#xD;
          8. Urinalysis has indicated that the urine protein is ≥ ++ and quantitative test of urine&#xD;
             protein has confirmed that the 24-h urine protein is &gt; 1.0 g.&#xD;
&#xD;
          9. Have a thrombosis tendency or are currently receiving thrombolysis/anticoagulation&#xD;
             therapy.&#xD;
&#xD;
         10. Have received major surgery within 4 weeks prior to randomization; or palliative&#xD;
             radiotherapy within 2 weeks prior to randomization; or have not recovered from the&#xD;
             toxicities and/or complications of previous interventions to NCI-CTCAE Grade ≤ 1.&#xD;
&#xD;
         11. Have known history of arterial/venous thrombosis within 6 months prior to&#xD;
             randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary&#xD;
             embolism.&#xD;
&#xD;
         12. Have received prior therapy with anti-PD-1/PD-L1 monoclonal antibodies, anti-CTLA-4&#xD;
             monoclonal antibodies, or small molecule VEGFR inhibitors.&#xD;
&#xD;
         13. Have known allergies to other monoclonal antibodies or any component of famitinib.&#xD;
&#xD;
         14. Are currently participating and receiving study therapy or have participated in a&#xD;
             study and received the last dose of study drug within 4 weeks (or 5 half-lives of the&#xD;
             study drug) prior to randomization.&#xD;
&#xD;
         15. Have other potential factors that may affect the study results or result in the&#xD;
             premature discontinuation as determined by the investigator, such as alcoholism, drug&#xD;
             abuse, substance abuse, other serious diseases (including mental illness) requiring&#xD;
             concomitant treatment, serious laboratory abnormalities, or family or social factors&#xD;
             that could affect the safety of medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>weixia Li, M.M</last_name>
    <phone>+86-15005136260</phone>
    <email>Weixia.li@hengrui.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

